Additionally, there are significant cost and resource implications to the NHS in treating hepatitis-related liver disease.
Yn ogystal, mae goblygiadau sylweddol o ran costau ac adnoddau i'r GIG o drin clefyd yr afu cysylltiedig â hepatitis.